Tarsus Pharmaceuticals, Inc. (TARS) financial statements and ratios from SEC XBRL: revenue $451.36M (TTM), net margin -14.7%, revenue growth 146.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $451.36M |
| Net Margin | -14.7% |
| Revenue Growth (YoY) | 146.7% |
| EPS Growth (YoY) | -48.2% |
| FCF Growth (YoY) | -73.6% |
| Price / Book | 8.82 |
| Price / Sales | 6.66 |
| FCF Yield | -4.5% |
| Altman Z-Score | 8.50 (safe) |
| Sector P/E (Healthcare) | 21.6 |
TARS overview · TARS earnings · TARS KPIs · TARS investor relations · TARS ownership · TARS peers · TARS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.